PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients

doi:10.3748/wjg.v24.i5.631

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9187)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

490

WORD

200

HTML

4772

Figures (1-2)

273

Tables (1-4)

305

Sum=6040

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

996

Download

2151

Sum=3147

Feb 7, 2018 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 7, 2018; 24(5): 631-640
Published online Feb 7, 2018. doi: 10.3748/wjg.v24.i5.631

Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival analysis for overall survival according to the PIK3CA kinase domain mutation status in stage II/III patients.

Citation: Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L. PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. World J Gastroenterol 2018; 24(5): 631-640
URL: https://www.wjgnet.com/1007-9327/full/v24/i5/631.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i5.631